148 related articles for article (PubMed ID: 15930293)
1. BRCA2 suppresses cell proliferation via stabilizing MAGE-D1.
Tian XX; Rai D; Li J; Zou C; Bai Y; Wazer D; Band V; Gao Q
Cancer Res; 2005 Jun; 65(11):4747-53. PubMed ID: 15930293
[TBL] [Abstract][Full Text] [Related]
2. BRCA2 suppresses replication stress-induced mitotic and G1 abnormalities through homologous recombination.
Feng W; Jasin M
Nat Commun; 2017 Sep; 8(1):525. PubMed ID: 28904335
[TBL] [Abstract][Full Text] [Related]
3. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
[TBL] [Abstract][Full Text] [Related]
4. Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2.
Wong JM; Ionescu D; Ingles CJ
Oncogene; 2003 Jan; 22(1):28-33. PubMed ID: 12527904
[TBL] [Abstract][Full Text] [Related]
5. MAGE-D1 inhibits proliferation, migration and invasion of human breast cancer cells.
Du Q; Zhang Y; Tian XX; Li Y; Fang WG
Oncol Rep; 2009 Sep; 22(3):659-65. PubMed ID: 19639218
[TBL] [Abstract][Full Text] [Related]
6. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.
Monte M; Simonatto M; Peche LY; Bublik DR; Gobessi S; Pierotti MA; Rodolfo M; Schneider C
Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11160-5. PubMed ID: 16847267
[TBL] [Abstract][Full Text] [Related]
7. Low incidence of BRCA2 mutations in breast carcinoma and other cancers.
Teng DH; Bogden R; Mitchell J; Baumgard M; Bell R; Berry S; Davis T; Ha PC; Kehrer R; Jammulapati S; Chen Q; Offit K; Skolnick MH; Tavtigian SV; Jhanwar S; Swedlund B; Wong AK; Kamb A
Nat Genet; 1996 Jun; 13(2):241-4. PubMed ID: 8640236
[TBL] [Abstract][Full Text] [Related]
8. BRCA2 monoclonal antibodies react with differentiating epithelium.
Gilliam LK; Lobenhofer EK; Greer PK; Scearce RM; Cirisano FD; Marks JR; Hale LP
Hybrid Hybridomics; 2002 Aug; 21(4):261-9. PubMed ID: 12193279
[TBL] [Abstract][Full Text] [Related]
9. Expression of MAGE-A11 in breast cancer tissues and its effects on the proliferation of breast cancer cells.
Xia LP; Xu M; Chen Y; Shao WW
Mol Med Rep; 2013 Jan; 7(1):254-8. PubMed ID: 23064813
[TBL] [Abstract][Full Text] [Related]
10. Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues.
Rajan JV; Marquis ST; Gardner HP; Chodosh LA
Dev Biol; 1997 Apr; 184(2):385-401. PubMed ID: 9133444
[TBL] [Abstract][Full Text] [Related]
11. Silencing of BRCA2 decreases anoikis and its heterologous expression sensitizes yeast cells to acetic acid-induced programmed cell death.
Guaragnella N; Marra E; Galli A; Moro L; Giannattasio S
Apoptosis; 2014 Sep; 19(9):1330-41. PubMed ID: 24902638
[TBL] [Abstract][Full Text] [Related]
12. Ultraviolet irradiation induces BRCA2 protein depletion through a p53-independent and protein synthesis-dependent pathway.
Wang SC; Makino K; Su LK; Pao AY; Kim JS; Hung MC
Cancer Res; 2001 Apr; 61(7):2838-42. PubMed ID: 11306454
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair.
Song L; Dai T; Xie Y; Wang C; Lin C; Wu Z; Ying Z; Wu J; Li M; Li J
J Mol Cell Biol; 2012 Apr; 4(2):108-17. PubMed ID: 22158906
[TBL] [Abstract][Full Text] [Related]
14. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
Moynahan ME
Oncogene; 2002 Dec; 21(58):8994-9007. PubMed ID: 12483515
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2.
Liu J; Yuan Y; Huan J; Shen Z
Oncogene; 2001 Jan; 20(3):336-45. PubMed ID: 11313963
[TBL] [Abstract][Full Text] [Related]
16. Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair.
Arnold K; Kim MK; Frerk K; Edler L; Savelyeva L; Schmezer P; Wiedemeyer R
Cancer Lett; 2006 Nov; 243(1):90-100. PubMed ID: 16448746
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 6 inhibits proliferation of human mammary epithelial cells.
Lucas JJ; Domenico J; Gelfand EW
Mol Cancer Res; 2004 Feb; 2(2):105-14. PubMed ID: 14985467
[TBL] [Abstract][Full Text] [Related]
18. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein.
Lomonosov M; Anand S; Sangrithi M; Davies R; Venkitaraman AR
Genes Dev; 2003 Dec; 17(24):3017-22. PubMed ID: 14681210
[TBL] [Abstract][Full Text] [Related]
19. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Andres JL; Fan S; Turkel GJ; Wang JA; Twu NF; Yuan RQ; Lamszus K; Goldberg ID; Rosen EM
Oncogene; 1998 Apr; 16(17):2229-41. PubMed ID: 9619832
[TBL] [Abstract][Full Text] [Related]
20. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
